Latest Pharmaceutical and Healthcare disease pipeline guide Hepatocellular Carcinoma – Pipeline Review, H1 2018, provides an overview of the Hepatocellular Carcinoma pipeline landscape.

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Hepatocellular Carcinoma – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hepatocellular Carcinoma , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatocellular Carcinoma pipeline guide also reviews of key players involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are:- 2, 1, 18, 76, 60, 1, 3, 92, 13 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 10, 6, 1, 1, 25 and 1 molecules, respectively.

Hepatocellular Carcinoma pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Companies Mentioned in Hepatocellular Carcinoma are: AbbVie Inc, Abivax SA, ACEA Biosciences Inc, Adaptimmune Therapeutics Plc, Advenchen Laboratories LLC, Alnylam Pharmaceuticals Inc, American Gene Technologies International Inc, Amgen Inc, AndroScience Corp, ArQule Inc, Array BioPharma Inc, Aslan Pharmaceuticals Pte Ltd, AstraZeneca Plc, AVEO Pharmaceuticals Inc, Bavarian Nordic A/S, Bayer AG, BeiGene Ltd, Bio-Cancer Treatment International Ltd, Biomics Biotechnologies Co Ltd, Bioneer Corp, Blueprint Medicines Corp, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Co, Can-Fite BioPharma Ltd, CARsgen Therapeutics Ltd, CASI Pharmaceuticals Inc, CBT Pharmaceuticals Inc, CCRP Therapeutics GmbH, Celgene Corp, Cellular Biomedicine Group Inc, Celsion Corp, China Medical System Holdings Ltd, Chipscreen Biosciences Ltd, Chugai Pharmaceutical Co Ltd, Conatus Pharmaceuticals Inc, Curevac AG, Delcath Systems Inc, Double Bond Pharmaceutical International AB, eFFECTOR Therapeutics Inc, Eiger BioPharmaceuticals Inc, Eisai Co Ltd, Eli Lilly and Co, Epeius Biotechnologies Corp, Epizyme Inc, Eureka Therapeutics Inc, Exelixis Inc, F. Hoffmann-La Roche Ltd, Faron Pharmaceuticals Oy, Galaxy Biotech LLC, GC Pharma, Genelux Corp, Genentech Inc, Genoscience Pharma, Genosco Inc, Gilead Sciences Inc, GlaxoSmithKline Plc, Golden Biotechnology Corp, H3 Biomedicine Inc, Hanmi Pharmaceuticals Co Ltd, Horizon Pharma Plc, Immatics Biotechnologies GmbH, Immunicum AB, Immunitor Inc, Immunomedics Inc, Immunovative Therapies Ltd, In-Cell-Art SAS, Incyte Corp, Inovio Pharmaceuticals Inc, Inspyr Therapeutics Inc, InteRNA Technologies BV, Jiangsu Hengrui Medicine Co Ltd, Johnson & Johnson, KAHR medical Ltd, Karcinolys SAS, Kite Pharma Inc, Komipharm International Co Ltd, Kowa Co Ltd, Kura Oncology Inc, Leap Therapeutics Inc, Lixte Biotechnology Holdings Inc, MaxCyte Inc, MedImmune LLC, Medivir AB, MELEMA Pharma GmbH, Merck & Co Inc, Merck KGaA, Merrimack Pharmaceuticals Inc, Midatech Pharma Plc, Millennium Pharmaceuticals Inc, Mina Therapeutics Ltd, Molecular Templates Inc, MTG Biotherapeutics Inc, MultiCell Technologies Inc, NeuroVive Pharmaceutical AB, Nkarta Inc, NormOxys Inc, Novartis AG, NovaTarg Therapeutics Inc, Nymox Pharmaceutical Corp, Omeros Corp, Oncolys BioPharma Inc, Oncolytics Biotech Inc, Oneness Biotech Co Ltd, Ono Pharmaceutical Co Ltd, Oxford BioTherapeutics Ltd, PepVax Inc, Pfizer Inc, Pharma Mar SA, PharmAbcine Inc, PharmaEssentia Corp, Phosplatin Therapeutics LLC, Provecs Medical GmbH, Provectus Biopharmaceuticals Inc, Q BioMed Inc, RedHill Biopharma Ltd , Regulus Therapeutics Inc, Rexahn Pharmaceuticals Inc, Samumed LLC, Saronic Biotechnology Inc, Sensei Biotherapeutics Inc, Shanghai Henlius Biotech Co Ltd, Shenogen Pharma Group Ltd, Sillajen Biotherapeutics , Simcere Pharmaceutical Group, Spring Bank Pharmaceuticals Inc, Sun Pharma Advanced Research Company Ltd, Takeda Pharmaceutical Co Ltd, TC BioPharm Ltd, Tessa Therapeutics Pte Ltd, Therapure Biopharma Inc, Tiziana Life Sciences Plc, TRACON Pharmaceuticals Inc, Trovagene Inc, Tumorend LLC, Twoxar Inc, Tyrogenex Inc, VasGene Therapeutics Inc, Verlyx Pharma Inc, VG Life Sciences Inc, Vicus Therapeutics LLC, Xencor Inc, Xspray Pharma AB, Yooyoung Pharm Co Ltd, Zhejiang Conba Pharmaceutical Co Ltd


Request for a Sample Copy of this Research Report at:


  1. The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma.
    2. The pipeline guide reviews pipeline therapeutics for Hepatocellular Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources.
    3. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    4. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    5. The pipeline guide reviews key companies involved in Hepatocellular Carcinoma therapeutics and enlists all their major and minor projects.
    6. The pipeline guide evaluates Hepatocellular Carcinoma therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    7. The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    8. The pipeline guide reviews latest news related to pipeline therapeutics for Hepatocellular Carcinoma

Browse full Report at:

Reasons to buy this Report:

1. procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
2. Find and recognize significant and varied types of therapeutics under development for Hepatocellular Carcinoma.
Classify potential new clients or partners in the target demographic.
3. Develop tactical initiatives by understanding the focus areas of leading companies.
4. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
5. Formulate corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics.
6. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
7. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Important Points Covered In Table of Content are:

Therapeutics Assessment, Assessment by Target, Assessment by Mechanism of Action, Assessment by Route of Administration, Assessment by Molecule Type, Pipeline Overview, Pipeline by Companies, Pipeline by Universities/Institutes, Products under Development by Companies, Products under Development by Universities/Institutes.